Topiramate vs placebo: Acceptability. Participants experiencing troublesome adverse effects of any nature
Topiramate showed no clear difference in acceptability with topiramate (endpoint: 12 weeks) Number of… compared with placebo (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Topiramate vs placebo Acceptability with topiramate (endpoint: 12 weeks) Number of participants experiencing troublesome side effects of any nature · adults with acute affective episodes in bipolar disorder Topiramate showed no clear difference in acceptability with topiramate (endpoint: 12 weeks) Number of… compared with placebo (low certainty). Topiramate for acute affective episodes in bipolar disorder in adults (2016) · Cochrane Headline outcomes only | OR 0.68 [0.33, 1.4] | 1 study · 212 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Topiramate for acute affective episodes in bipolar disorder in adults 2016 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.